depressed, depression, moody, melancholy

Depressed Jane

Let Me Tell You More About My Depressed, Miserable Existence

Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression

Auspex Pharmaceuticals, a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI). Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of Major Depressive Disorder.

Popularity: unranked [?]

Post to Twitter Post to Delicious Post to Digg Post to Facebook Post to Reddit

Related posts:

  1. Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression
  2. Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder
  3. New Study Results Provide Additional Data About Short- And Long-Term Use Of Desvenlafaxine Succinate In The Treatment Of Major Depressive Disorder
  4. FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
  5. Antidepressants: Benefit Of SNRI Is Proven

Comments

No Responses to “Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression”

Write a Comment